Scancell, the developer of therapeutic cancer vaccines, lost around one-eighth of its value following full year results.
The sharp fall ppears to be profit taking following an amazing price performance over the last few months.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The company, which is still very much in development phase, received a milestone payment from Arana Therapeutics of £2.49m net of costs during a year in which development costs rose.
For the year ending 30th April 2012, Scancell reported pre-tax profits of £557,058 (2011: loss of £1.65m). It also had £3.5m cash at year end (2011: 1.10m), largely as a result of the placing of £1.58m in shares.
Phase II of the clinical trials for SCIB1 in melanoma began in May 2012 and is on schedule to be completed by the end of 2013.
It is also looking for a partner to fund further development on it SCIB2 vaccine for certain types of cancer.
CM
-
How to pay in a chequeReceiving or writing a cheque has become much less common in recent years as instant bank transfers have grown in popularity. Amid widespread bank branch closures, we explain what to do if you get a cheque, and how you can pay one into your bank account.
-
Crypto assets of seven million UK investors at risk – how to keep yours safeCryptocurrency wallet rules make it hard to track down assets after someone has died, even if they leave a will saying who they would like to inherit them
